These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 34282198)

  • 21. Net-clinical benefit of extended prophylaxis of venous thromboembolism with betrixaban in medically ill patients aged 80 or more.
    Ageno W; Lopes RD; Yee MK; Hernandez A; Hull RD; Goldhaber SZ; Gibson CM; Cohen AT
    J Thromb Haemost; 2019 Dec; 17(12):2089-2098. PubMed ID: 31392827
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Periprocedural Outcomes of Direct Oral Anticoagulants Versus Warfarin in Nonvalvular Atrial Fibrillation.
    Nazha B; Pandya B; Cohen J; Zhang M; Lopes RD; Garcia DA; Sherwood MW; Spyropoulos AC
    Circulation; 2018 Oct; 138(14):1402-1411. PubMed ID: 29794081
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rivaroxaban: an oral factor Xa inhibitor.
    Thomas TF; Ganetsky V; Spinler SA
    Clin Ther; 2013 Jan; 35(1):4-27. PubMed ID: 23328267
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rivaroxaban versus Aspirin in Prevention of Venous Thromboembolism: A Meta-Analysis of 9 Randomized Controlled Trials comprising 7,656 Patients.
    Xie J; Jiang M; Lin Y; Deng H; Xie X; Li L
    Thromb Haemost; 2019 Sep; 119(9):1517-1526. PubMed ID: 31365943
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism.
    Robertson L; Strachan J
    Cochrane Database Syst Rev; 2017 Feb; 2(2):CD006771. PubMed ID: 28195640
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation.
    Fox KAA; Lucas JE; Pieper KS; Bassand JP; Camm AJ; Fitzmaurice DA; Goldhaber SZ; Goto S; Haas S; Hacke W; Kayani G; Oto A; Mantovani LG; Misselwitz F; Piccini JP; Turpie AGG; Verheugt FWA; Kakkar AK;
    BMJ Open; 2017 Dec; 7(12):e017157. PubMed ID: 29273652
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Systemic treatments for the prevention of venous thrombo-embolic events in paediatric cancer patients with tunnelled central venous catheters.
    Schoot RA; Kremer LC; van de Wetering MD; van Ommen CH
    Cochrane Database Syst Rev; 2013 Sep; (9):CD009160. PubMed ID: 24026801
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Systematic review: case-fatality rates of recurrent venous thromboembolism and major bleeding events among patients treated for venous thromboembolism.
    Carrier M; Le Gal G; Wells PS; Rodger MA
    Ann Intern Med; 2010 May; 152(9):578-89. PubMed ID: 20439576
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of Apixaban on All-Cause Death in Patients with Atrial Fibrillation: a Meta-Analysis Based on Imputed Placebo Effect.
    Guimarães PO; Lopes RD; Wojdyla DM; Abdul-Rahim AH; Connolly SJ; Flaker GC; Wang J; Hanna M; Granger CB; Wallentin L; Lees KR; Alexander JH; McMurray JJV
    Cardiovasc Drugs Ther; 2017 Jun; 31(3):295-301. PubMed ID: 28516318
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel oral anticoagulants in atrial fibrillation: a meta-analysis of large, randomized, controlled trials vs warfarin.
    Dogliotti A; Paolasso E; Giugliano RP
    Clin Cardiol; 2013 Feb; 36(2):61-7. PubMed ID: 23338902
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Net clinical benefit of edoxaban versus no treatment in a 'real world' atrial fibrillation population: A modelling analysis based on a nationwide cohort study.
    Blann AD; Banerjee A; Lane DA; Torp-Pedersen C; Lip GY
    Int J Cardiol; 2015 Dec; 201():693-8. PubMed ID: 26379097
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anticoagulation risk assessment for patients with non-valvular atrial fibrillation and venous thromboembolism: A clinical review.
    Pallazola VA; Kapoor RK; Kapoor K; McEvoy JW; Blumenthal RS; Gluckman TJ
    Vasc Med; 2019 Apr; 24(2):141-152. PubMed ID: 30755150
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Meta-analysis on anticoagulation and prevention of thrombosis and mortality among patients with lung cancer.
    Fuentes HE; Oramas DM; Paz LH; Casanegra AI; Mansfield AS; Tafur AJ
    Thromb Res; 2017 Jun; 154():28-34. PubMed ID: 28402864
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of testing for cancer on cancer- and venous thromboembolism (VTE)-related mortality and morbidity in people with unprovoked VTE.
    Robertson L; Yeoh SE; Stansby G; Agarwal R
    Cochrane Database Syst Rev; 2017 Aug; 8(8):CD010837. PubMed ID: 28832905
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation.
    Wallentin L; Lopes RD; Hanna M; Thomas L; Hellkamp A; Nepal S; Hylek EM; Al-Khatib SM; Alexander JH; Alings M; Amerena J; Ansell J; Aylward P; Bartunek J; Commerford P; De Caterina R; Erol C; Harjola VP; Held C; Horowitz JD; Huber K; Husted S; Keltai M; Lanas F; Lisheng L; McMurray JJ; Oh BH; Rosenqvist M; Ruzyllo W; Steg PG; Vinereanu D; Xavier D; Granger CB;
    Circulation; 2013 Jun; 127(22):2166-76. PubMed ID: 23640971
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of direct oral anticoagulants approved for cardiovascular indications: Systematic review and meta-analysis.
    Makam RCP; Hoaglin DC; McManus DD; Wang V; Gore JM; Spencer FA; Pradhan R; Tran H; Yu H; Goldberg RJ
    PLoS One; 2018; 13(5):e0197583. PubMed ID: 29795629
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Apixaban versus enoxaparin in patients with total knee arthroplasty. A meta-analysis of randomised trials.
    Huang J; Cao Y; Liao C; Wu L; Gao F
    Thromb Haemost; 2011 Feb; 105(2):245-53. PubMed ID: 20941455
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative effectiveness of warfarin and new oral anticoagulants for the management of atrial fibrillation and venous thromboembolism: a systematic review.
    Adam SS; McDuffie JR; Ortel TL; Williams JW
    Ann Intern Med; 2012 Dec; 157(11):796-807. PubMed ID: 22928173
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical Effectiveness and Safety of Aspirin for Venous Thromboembolism Prophylaxis After Total Hip and Knee Replacement: A Systematic Review and Meta-analysis of Randomized Clinical Trials.
    Matharu GS; Kunutsor SK; Judge A; Blom AW; Whitehouse MR
    JAMA Intern Med; 2020 Mar; 180(3):376-384. PubMed ID: 32011647
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of double-blind vs. open study design on the observed treatment effects of new oral anticoagulants in atrial fibrillation: a meta-analysis.
    Lega JC; Mismetti P; Cucherat M; Fassier T; Bertoletti L; Chapelle C; Laporte S
    J Thromb Haemost; 2013 Jul; 11(7):1240-50. PubMed ID: 23659614
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.